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Abstract
 
 
 
 selection is a major checkpoint in early thymocyte differentiation, mediated by successful ex-
pression of the pre-T cell receptor (TCR) comprising the TCR
 
 
 
 chain, CD3 proteins, and a
surrogate TCR
 
 
 
 chain, pT
 
 
 
. The mechanism of action of the pre-TCR is unresolved. In hu-
 
mans and mice, the pT
 
 
 
 gene encodes two RNAs, pT
 
 
 
a
 
, and a substantially truncated form,
pT
 
 
 
b
 
. This study shows that both are biologically active in their capacity to rescue multiple
thymocyte defects in pT
 
 
 
 
 
/
 
 
 
 mice. Further active alleles of pT
 
  
 
include one that lacks both
the major ectodomain and much of the long cytoplasmic tail (which is unique among antigen
receptor chains), and another in which the cytoplasmic tail is substituted with the short tail of
TCR C
 
 
 
. Thus, very little of the pT
 
 
 
 chain is required for function. These data support a hy-
pothesis that the primary role of pT
 
  
 
is to stabilize the pre-TCR, and that much of the con-
served structure of pT
 
 
 
 probably plays a critical regulatory role.
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/
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Introduction
 
Most 
 
 
 
/
 
 
 
 thymocytes develop and mature within the
thymus. Progression through this intrathymic differentia-
tion can be defined by the sequential expression of partic-
ular cell surface markers. Thus, whereas most mature 
 
 
 
/
 
 
 
T cells express either CD4 or CD8 coreceptors, their ear-
 
liest immature thymic progenitors are CD4
 
 
 
CD8
 
 
 
 dou-
ble negative (DN). The earliest such DN progenitors ex-
press high levels of heat stable antigen (HSA) and CD44
(DN subset I), whereafter the cells acquire CD25 (DN
II), then lose CD44 (DN III) and subsequently CD25
(DN IV) (1).
Although these subset classifications are purely opera-
tional and mask additional heterogeneity within each sub-
set, the onset of TCR 
 
 
 
 gene rearrangement can be largely
attributed to DN II and DN III. Only those thymocytes
that succeed in generating a functional TCR
 
 
 
 chain selec-
tively survive through the transition from DN III to DN
IV (2, 3). As a result of such “
 
 
 
 selection,” cells survive,
become activated, expand in size, and proliferate rapidly
 
before acquiring CD4 and CD8 (4). Such CD4
 
 
 
CD8
 
 
 
double-positive (DP) cells account for the majority
 
(
 
 
 
80%) of thymocytes (5).
 
 
 
 selection is mediated by the pre-TCR which consists
of—at minimum—the 
 
 
 
 chain, CD3 components, and a
surrogate TCR
 
 
 
 chain termed pre-T
 
 
 
 (pT
 
 
 
) (6, 7, 8).
Thymocyte differentiation in mice deficient in components
of the pre-TCR, or in signaling molecules downstream of
it, are inhibited in their transition across “
 
 
 
 selection” (9,
10). Therefore, in pT
 
 
 
 
 
/
 
 
 
 mice there are very few DP
cells, and the total number of thymocytes is usually only
1–10% of normal. Those DP cells that develop are largely
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driven by the contribution of TCR
 
 
 
/
 
 
 
 or the precocious
expression of TCR
 
 
 
/
 
 
 
 (11, 12). Furthermore, it has been
reported that thymocytes in pT
 
 
 
 
 
/
 
 
 
 mice more commonly
express two productively rearranged TCR
 
 
 
 chain genes,
suggesting a defect in allelic exclusion (13).
By contrast, 
 
 
 
/
 
 
 
 cell differentiation does not depend on
pT
 
 
 
, and in pT
 
 
 
 
 
/
 
 
 
 mice, 
 
 
 
/
 
 
 
 cell numbers are conspic-
uously increased. In particular, there occurs a subset of 
 
 
 
/
 
 
 
cells coexpressing CD4 that is not readily detected in nor-
mal mice (14). Such observations are consistent with the
proposal that 
 
  
 
/
 
  
 
 lineage determination in thymocytes
is somewhat flexible, strongly affected by the expression
of TCR chains and of the pre-TCR (15, 16). In sum, the
pre-TCR promotes a maturational program that includes
cell survival; cell activation and growth; proliferation; dif-
ferentiation to DP cells; the arrest of further 
 
 
 
 chain gene
rearrangement; and possibly fate determination. Hence,
the mechanism of action of the pre-TCR is of consider-
able interest.
The pT
 
 
 
 genes in mice and humans each give rise to
two transcripts (17, 18). One, pT
 
 
 
a
 
, encodes a transmem-
brane protein comprising a single Ig-like extracellular do-
main of 
 
 
 
110 amino acids, a transmembrane domain con-
taining two charged amino acids, and a COOH terminal
cytoplasmic region of 
 
 
 
30 amino acids (7). This COOH
tail distinguishes pT
 
 
 
 from other TCR or Ig chains that
lack cytoplasmic regions of anything greater than a few
amino acids. The second transcript, pT
 
 
 
b
 
, splices out the
second exon encoding the Ig-like ectodomain, and could
therefore produce a significantly smaller isoform with very
limited capacity to interact with molecules extracellularly
(17). One important question is whether both naturally oc-
curring alleles of pT
 
 
 
 can promote thymocyte develop-
ment, or whether the smaller form might be an inactive
isoform that might, for example, perform a regulatory role.
In this paper, a genetic complementation approach has
been used to answer this question. Additionally, this paper
examines which regions of the pT
 
 
 
 protein are required
for biological activity.
Because the pre-TCR is expressed in vivo at very low
levels, and because there are few cell lines representative of
immature thymocytes, there has been little biochemical
characterization of the pre-TCR. Likewise, there has been
no identification of a pre-TCR ligand. Instead, information
on the active form of the pre-TCR has been gained prima-
rily from genetic or cell biological experiments. Such ex-
periments have provided some seemingly contradictory ob-
servations. First, a truncated pT
 
 
 
 chain which lacks the
highly conserved extracellular Ig-like loop can, together
with a truncated TCR
 
 
 
 chain, restore the development of
DP cells in mice that are deficient in recombinase activat-
ing genes (RAG) 1 or 2, and that as a result cannot rear-
range their endogenous TCR
 
 
 
 chain genes (19). This
result seems consistent with studies indicating that the pre-
TCR can aggregate in the plasma membrane with lck in
detergent insoluble glycolipids (DiGs), commonly termed
rafts, even in the absence of any overt ligand (20). By this
view, the more important components of pT
 
 
 
 would ap-
 
pear to be the charged transmembrane domain that facili-
tates pairing with CD3; a juxtamembrane cysteine in the
intracellular tail that may contribute to raft association; and
any other components of the cytoplasmic tail that regulate
signaling or pre-TCR stability. In particular, there is a pro-
line-rich motif, occurring once in human pT
 
 
 
 and re-
peated in murine pT
 
 
 
 that has similarities to protein kinase
C substrate sites (7), and to regions in CD2 that mediate
signal transduction by binding to CD2BP2 (21). Indeed, in
somatic cell transfection studies, mutants lacking the pro-
line motifs show differences in properties compared with
full length versions (unpublished data). However, other ex-
periments indicate that thymocyte development in pT
 
 
 
 
 
/
 
 
 
mice can be rescued by a pT
 
 
 
 allele lacking the bulk of the
cytoplasmic tail (14). Combining these data, one might hy-
pothesize that only a very small portion of pT
 
 
 
 (
 
 
 
80
amino acids), lacking much of the ectodomain and its intra-
cellular region, is required for biological activity. This hy-
pothesis is confirmed in this report. The implications of
these findings and of the transgenic methodologies com-
monly used in such studies are discussed.
 
Materials and Methods
 
Generation of Transgenic Mice.
 
cDNAs of the different pT
 
 
 
forms were generated by PCR. The full length pT
 
 
 
a
 
, “p600,”
and the second isoform, pT
 
 
 
b
 
, “p300,” have been made previ-
ously (17). Truncated forms of pT
 
 
 
a
 
 and pT
 
 
 
b
 
, named p600
 
 
 
P
and p300
 
 
 
P, respectively, in which the last cytoplasmic 16 amino
acids (containing the two proline rich regions and the two poten-
tial PKC phosphorylation sites) were deleted, were generated by
PCR using the following primers: for p600
 
 
 
P, 5
 
 
 
-AATAGAT-
CTCTACCATCAGGCATCGCT-3
 
 
 
 and 5
 
 
 
-AATCCGCGGCT-
ACTGGAGGTGCTGGCCCGC-3
 
 
 
. For p300
 
 
 
P, 5
 
 
 
-AATAGA-
TCTCTACCATCAGGGGAATCT-3
 
  and 5 -AATCCGCGG-
CTACTGGAGGTGCTGGCCCGC-3 . The pT C  construct,
in which the connecting peptide, transmembrane region, and cyto-
plasmic tail of p600 were substituted with those of TCR-C , was
generated in two fragments using two sets of primers. For the
5  part of pT C , 5 -AATAGATCTCTACCATCAGGCA-
TCGCT-3  and 5 -AGCACACACCCCCTCCAGCTGTC-
AGACGTTCCCTGTGATGCCACGTTGACCGAG-3 . For
the 3  part of pT C , 5 -CTCGGTCAACGTGGCATCAC-
AGGGAACGTCTGACAGCTGGAGGGGGTGTGTGCT-3 
and 5 -AATCCGCGGTCAACTGGACCACAGCCTCAG-
CGT-3 . Both PCR products were annealed for 30 min at 45 C,
and subsequently amplified using the primers 5 -AATAGATCT-
CTACCATCAGGCATCGCT-3  and 5 -AATCCGCGGT-
CAACTGGACCACAGCCTCAGCGT-3 .
In each case, products were cloned in-frame (via BglII/SacII)
into the expression vector pDisplay (Invitrogen). The Ig  leader
sequence, HA tag, and cDNA were then subcloned from pDis-
play into the BamH1 site of the T cell lineage–specific expression
vector, p1017 (22, 23). A Not1-Not1 fragment from p1017 was
then microinjected into C57.BL6   SJL zygotes, that were im-
planted into pseudopregnant females. Progeny were screened by
PCR and Southern, and transgenic lines crossed to pT  / .
Isolation of Lymphocytes. Intraepithelial lymphocytes were
harvested as described (24). Single thymocyte suspensions were
obtained by crushing whole thymi between the edges of frosted697 Gibbons et al. Brief Definitive Report
glass slides into FACS® buffer (1  PBS/2% FCS/0.1% azide).
Live cells were determined by trypan blue exclusion.
Flow Cytometry. Thymocytes or intestinal intraepithelial lym-
phocytes at  2   107/ml were stained with the antibodies listed
below and analyzed, on either a FACStarPlus™ (Becton Dickinson)
or a FACS Vantage™ (Becton Dickinson) flow cytometer. Data
were analyzed with CELLQuest™ software. Monoclonal anti-
body reagents obtained from BD PharMingen were:  CD4-
FITC (GK1.5),  CD8 -PE (53–6.7),  CD25-FITC (7D4),
 CD44-APC (IM7),  CD44-cy-Chrome (IM7),  HSA-PE
(M1/69),   TCR    -PE (H57–597),  TCR    -PE (GL3),
 CD3 -biotin (145–2C11). Other antibodies and reagents for
flow cytometry included avidin Red670 (GIBCO BRL) and rat
normal serum (GIBCO BRL).
RNA Isolation, cDNA Synthesis, and Semiquantitative PCR.
RNA isolated using Trizol reagent (GIBCO BRL) was DNase
treated (GIBCO BRL) and quantitated by spectrophotometry.
AMV reverse transcriptase (Roche) reactions were primed with
Pd(N) (Amersham Pharmacia Biotech). Standard reverse tran-
scription (RT)-PCRs using 200 ng thymocyte RNA from
pT  /  transgenic, and nontransgenic littermates used primers as
follows: HA-For, 5 -CCA TAT GAT GTT CCA GAT TAT
GCT-3 ;  P1 P2-Rev, 5 -CTG GAG GTG CTG GCC CGC-
3 ; PTA REV, 5 -CTA TGT CCA AAT TCT GTG GGT-3 ;
HGH REV, 5 -GGA TAT AGG CTT CTT CAA AC-3 .
Immunoprecipitation and Immunoblotting. For immunoprecipi-
tations, 2   107 freshly isolated thymocytes or pT  transfectants
(17) were washed in cold PBS buffer, lysed in 300  l ice-cold ly-
sis buffer (20 mM Tris, pH 7.4, 150 mM NaCI, 1% NP-40,
0.25% Na-deoxycholate, 10 mM NaF, 10 mM Na4P2O7, 1 mM
EGTA, 1 mM MgCl2, 1 mM Na3VO4, 1 mM PMSF, 20  g/ml
aprotinin, 20  g/ml leupeptins, 10  g/ml Pepstatin A, 20  g/ml
antipain). Lysates were incubated for 20 min on ice before cen-
trifugation at 13,000 rpm for 15 min at 4 C. Postnuclear lysates
were agitated for 1 h at 4 C with 2  l anti-HA monoclonal anti-
body HA.11 (BabCO). 25  l protein A-Sepharose beads (Amer-
sham Pharmacia Biotech), swollen and washed in lysis buffer,
were added and incubated overnight at 4 C. The beads were
washed 3  in cold lysis buffer, and proteins eluted by boiling for
5 min in SDS sample buffer, separated by 15% SDS-PAGE gel,
and transferred to nitrocellulose for immunoblotting. The mem-
branes were blocked with 4% nonfat milk in TBS (10 mM Tris-
HCl, pH 7.6, 150 mM NaCl) and incubated with HA.11 (1:3,000).
Bound Ab was revealed with 1:8,000 diluted horseradish peroxi-
dase (HRP)-conjugated donkey anti–mouse IgG (Jackson Immu-
noResearch Laboratories) using Western blot chemiluminescence
reagent (NEN Life Science Products).
Allelic Exclusion. Single CD4 CD8  double-positive thy-
mocytes were sorted using a MoFlo high speed cell sorter (Cyto-
mation) into a 96-well plate, containing 10  l of PCR buffer
containing proteinase K (250  g/ml). Plates were incubated at
55 C for 1 h and then the proteinase K was inactivated by heating
at 95 C for 15 min. Plates were then stored at  20 C. TCR  re-
arrangements were amplified by a seminested two-step PCR us-
ing primers as described by Aifantis and colleagues (13, 25).
Briefly, 40  l of a mixture containing dNTPs, buffer, 3 pmol of
each V , D , and J  primer, and 0.1 U of Taq polymerase
(QIAGEN) was added to each well. Amplification comprised five
cycles in which the denaturing step was 96 C and the annealing
temperature decreased from 68–60 C, followed by a further 25
cycles (30 s at 94 C, 1 min at 58 C, 1 min at 72 C) and finally 7
min at 72 C. For the second round of amplification, 1  l of the
first round product was transferred into a fresh tube containing a
single 5  primer in conjunction with the nested J 1 or J 2 primer
(10 pmol of each), dNTPs, buffer, and Taq polymerase (0.1 U) in
final volume of 25  l. Amplification was for 35 cycles following
Figure 1. Schematic represen-
tation of different pT  trans-
genes and their expression. (A)
Schematic representation of the
five different pT  cDNAs con-
structed as described in Materials
and Methods. (B) Each of the
pT  cDNAs was cloned (to-
gether with a HA tag and Ig 
leader sequence) into the
BamH1 site of the p1017 vector.
The purified Not1 fragment of
p1017 recombinants was micro-
injected into the pronuclei of
fertilized eggs. (C) Reverse tran-
scription (RT)-PCR detection
of pT  mRNA expression from
thymocytes of the different pT 
transgenics. Transgenics positive
by genotyping ( ) gave a posi-
tive mRNA expression when
compared with those that were
negative by genotyping ( ).
GAPDH was positive in all sam-
ples. (D) The expression of p300
and p300 P protein in thy-
mocytes from transgenic mice
compared with protein expres-
sion in a p300 transfected cell
line. 7.1 kD denotes the migra-
tion of a protein size marker on
the same gel.698 Biologically Active pT  Alleles
the same procedure as the first round PCR (except denaturing
was always at 94 C). Rearrangements were detected by migration
of the PCR product on a 1.5% ethidium bromide stained agarose
gel and positives purified using QIAGEN purification kits. Direct
sequencing of the PCR products was performed using the Big-
Dye Ready Reaction sequencing mix (ABI) and automated se-
quencing performed on a 96 lane ABI 377 sequencer.
Results
Generation of Transgenic pT  /  Mice Expressing Different
Forms of pT b. To determine whether the naturally oc-
curring pT b gene and derivatives thereof could function-
ally promote thymocyte development, numerous lines of
transgenic mice were generated expressing either pT b
(p300) or a truncated form lacking the proline-rich regions
and much of the remainder of the cytoplasmic tail
(p300 P). As a positive control, mice were also generated
that expressed pT a (p600) or a corresponding cytoplasmic
tail deletion mutant (p600 P). Transgenic mice of the lat-
ter type have previously been reported (14). Additionally,
transgenic mice were generated that expressed a chimeric
cDNA encoding the extracellular region of pT  joined to
the connecting peptide, transmembrane, and intracellular
regions of the mature C  gene (pT C , Fig. 1 A). In
each case, relevant cDNAs were cloned into the p1017
vector, containing the lck proximal promoter to ensure
early T lineage expression (22, 23; Fig. 1 B). Transgenic
lines were established (genotyping not shown) and back-
crossed onto the pT  /  background, generating F2 ani-
mals that expressed the different transgenes in the absence
of endogenous pT .
In every case, pT  /  mice that genotyped positively for
a transgene showed transgene RNA expression in the thy-
mus (Fig. 1 C). As the emphasis of this manuscript is on the
biological activity of pT b, the expression of wild-type and
mutant forms of pT b protein was additionally examined
(Fig. 1 D). Levels detected by Western analysis of HA-
tagged protein in thymocyte lysates were comparable to
those in a pT b-transfected cell line (17, 26). Not surpris-
ingly, both RNA and protein expression varied markedly
among different founder transgenics, limiting the degree to
Figure 2. Restoration of phenotype by expres-
sion of pT  transgenes. (A) CD4 versus CD8 ex-
pression on thymocytes from pT  /  (left) and
p300 P.pT  /  (right). The percentage of thy-
mocytes in each quadrant are shown. (B) The per-
centage of DP (i.e., CD4 CD8 ) cells in the thymi
of mice expressing different pT  transgenes. Indi-
vidual vertical lines represent independent lines of
mice; individual data points on those vertical lines
represent the percentage of DP cells in the thymi of
individual mice. (C and D) The percentage of DN
 /  cells (C) or CD4   /  cells (D) in the thymi of
mice expressing different pT  transgenes. Individual
vertical lines represent independent lines of mice;
individual data points on those vertical lines repre-
sent the percentage of  /  cells in the thymi of indi-
vidual mice. (E)  Total cellularity of the thymus
( 106 cells) was established by trypan blue exclu-
sion. Individual vertical lines represent independent
lines of mice; individual data points on those vertical
lines represent the cell numbers in individual mice.699 Gibbons et al. Brief Definitive Report
which one should cross-compare phenotypes of transgenic
mice generated with different pT  alleles.
pT b Transgenes Induce DP Cell Representation. The sur-
face phenotypes of thymocytes in the pT  transgenic mice
were analyzed by flow cytometry. The majority of pT  / 
thymocytes are blocked as DN cells (Fig. 2 A). Conversely,
pT b, as well as the smallest transgene, p300 P, could
completely restore DP thymocyte representation (DP cells
are 84% of the total thymocyte number in 300 P mice,
compared with 7% in pT  /  mice; Fig. 2 A). The lack of
any essential functional requirement for the pT  cytoplas-
mic tail was confirmed by the restored phenotypes of pT -
C , and p600 P transgenic mice (Fig. 2 B). In all, substan-
tive restoration of DP differentiation was shown by at least
one line of transgenic mice generated with each of the alleles
(p300, p300 P, p600, p600 P, and pT -C ; Fig. 2 B).
pT b Transgenes Reduce  /  Cell Representation in the Thy-
mus and Gut. Normally, thymic  /  cells compose  1%
of thymocytes. These levels are increased to 5–20% of thy-
mocytes in pT  /  mice, and comprise both DN cells and
CD4   /  cells, a subset rarely detected in wild-type thymi
(Fig. 2, C and D). Conversely, the conventional, low level
of  /  cell representation (both DN and CD4 ) was re-
stored in transgenic pT  /  mice expressing the full length
or the truncated forms of pT b (Fig. 2, C and D). Indeed,
the normal phenotype was restored in at least one line of
transgenic mice generated with each of the five pT  alleles
under study (Fig. 2, C and D). In all cases the influence of
pre-TCR expression over the percentages of  /  cells cor-
related reasonably well with the absolute numbers of  / 
cells (Table I), indicating that changes in the percentages of
 /  cells are real changes and not simply an indirect effect
of changes in other cell subsets, e.g., DP thymocytes.
Consistent with the block in  /  T cell development in
pT  /  mice, the intestinal intraepithelial lymphocytes
(IELs) are depleted of  /  T cells, and instead comprise
 90%  /  cells (Table II). Because the representation of
 /  cells in the pT  /  thymus was significantly sup-
pressed by the expression of the small p300 P construct,
the question arose as to whether  /  cells would be simi-
larly reduced to normal levels in the gut. This was indeed
the case: IELs from pT  /  mice expressing the p300 P
transgene included fewer  /  cells than the pT  /  gut,
with a representation ( 50% of CD3  IELs) that was com-
parable to normal (Table II).
Hypocellularity of the pT  /  Thymus Is Rescued. The
thymi of 6–8-wk-old wild-type mice contain an average of
1.2   108 thymocytes, with a range of  0.9–1.9   108
cells. pT  /  mice contain 10–50-fold fewer thymocytes.
Two transgenic lines, one expressing p300 (pT b) and one
expressing p300 P showed rescue of an approximately
normal range (Fig. 2 E). In other lines, thymic cellularity
was often not well rescued even where there was substan-
tial and parallel restoration of normal DP and TCR /  
thymocyte phenotypes (Fig. 3). However, this does not re-
flect a failure of pT  transgenes to regulate cellularity be-
cause there is an additional effect whereby transgenes ex-
pressing either TCR chains or pre-TCR chains commonly
reduce thymus cellularity, even on a wild-type background
(unpublished data). As an example, two p600 P mice on a
pT  /  background contain 4.8   107 and 6.2   107 thy-
mocytes, respectively, while one p300 P pT  /  strain
contained 6.6   107 cells. The fact that these cell numbers,
albeit lower than normal, are comparable in transgenic
mice on a pT  /  or a pT   background indicates that
each of the trangenes has overcome the negative influence
of pT  deficiency on thymocyte numbers (see Discussion).
Allelic Exclusion Occurs in p300 P Mice. One compo-
nent of normal thymocyte development is allelic exclusion.
To test whether this occurs in the DP thymocyte compart-
ment that is restored in mice expressing the smallest pT 
transgene, p300 P, TCR  rearrangements were examined
by single cell PCR. Multiple primers were used that am-
plify many (but not all) V  segments, and that distinguish
rearrangements of V or D to J 1 or J 2. Products were ob-
tained from all cells analyzed. Conspicuously, the biased
V  usage seen in immature thymocytes of normal mice
(e.g., preferential usage of V 8) was also seen in the
p300 P pT  /  mice (27).
Table I. Percentage of  /  Cells Correlates Well with Absolute 
Cell Numbers
Transgenic
mouse
Mean percentage
of total
 /  cells
Mean DN
 /  cells
( 105)
Mean CD4 
 /  cells
( 104)
Wild type 0.64 1.2 4.8
p300 P 0.79 1.4 5.4
p300 1.11 2.2 2.2
p300 12 13 19
pT  /  16 12 21
The mean percentage of total  /  cells is compared with the absolute
numbers of DN ( 105) or CD4  ( 104)  /  cells in wild-type mice,
pT  /  mice, or in pT  /  mice expressing either p300 or p300 P
transgenes that did or did not recover normal phenotypes.
Table II. p300 P Transgene Expression Recovers  /  IELs
Wild type p300 Pp T   / 
Recovery ( 106) 6.8 14 13.1
Percent  /  cells 29.82 36.4 1.31
Percent  /  cells 54.49 51.63 86.8
Percent CD8  60 48.5 60.86
Percent CD8  14.2 30.3 1.93
Percent CD4 6.15 1.65 0.88
IELs were collected from wild-type, pT  / , and pT  /  mice
expressing the p300 P transgene. Cells were stained with the antibodies
indicated and the data represent the percentage of cells (mean of two
mice in each case) expressing the particular markers.700 Biologically Active pT  Alleles
Many cells gave more than two PCR products but when
these rearrangements were analyzed they corresponded to
DNA excision loops formed alongside correct chromo-
somal rearrangements. 25% of cells exhibited a single
in-frame VDJ rearrangement together with a DJ rearrange-
ment. A further 1/3 of cells showed only one rearrange-
ment which was an in-frame VDJ junction. The remaining
cells showed one in-frame VDJ rearrangement together
with a nonproductive VDJ rearrangement (Table III). No
cell tested produced more than one in frame VDJ rear-
rangement, indicating that allelic exclusion operates in the
p300 P transgenic mouse.
Discussion
This study has investigated whether the second naturally
occurring pT  transcript, pT b encodes a biologically ac-
tive pT  isoform. It has also asked whether thymocyte de-
velopment can be sustained by an even smaller pT b allele
that lacks both the major Ig-like ectodomain and the bulk
of the cytoplasmic tail. Finally, it has asked whether thy-
mocyte development can be functionally sustained by a
pT  allele in which the cytoplasmic tail has been ex-
changed for the short tail of C . The measurement of bio-
logical activity was the functional complementation of the
pT  /  mouse. The four primary defects reported in
pT  /  mice are: the paucity of DP thymocyte differentia-
tion (correlated with a relative increase in the percentage of
DN thymocytes); increases in TCR /   cells of both DN
and CD4  phenotypes; the failure of allelic exclusion at the
TCR  locus; and decreases in thymocyte numbers. Both
the full length and truncated alleles of pT b as well as the
pT -C  allele showed the capacity to largely or fully re-
store these phenotypes, although allelic exclusion was as-
sessed in only one of the strains (p300 P). Thus, highly
truncated forms of pT  are biologically active, including
the naturally occurring form, pT b that is conserved in hu-
mans and mice (17, 18). Interestingly, a targeted mutation
of the pT  locus that would be predicted to leave intact the
coding potential of pT b showed a very mild phenotype in
terms of altered thymocyte differentiation, consistent with
the idea that pT b is biologically active in vivo (10).
There is some contention over which of the four pri-
mary thymocyte defects reported in pT  /  mice reflect
direct targets of pT . More than one of these events may
be directly downstream of pT , but some may have greater
dependence on pT  function than do others. Data pre-
sented here show that all four parameters are rescued in at
least one line expressing either the full length or the heavily
truncated pT  alleles. Nonetheless, in several mice in
which thymocytes could be classified into largely normal
subset distributions, cellularity was not always normal (Fig.
3). Similar variability in thymus cellularity is evident when
data from other mice transgenic for pre-TCR components
are considered (14, 19). At minimum, these data demon-
strate that appropriate thymocyte differentiation can occur
independent of extensive proliferation. A similar situation
appears to characterize the IL-7 /  mouse (28).
The lack of normal cellularity seems in part due to an in-
hibitory effect of the expression of pT  transgenes, as a
similar reduction, relative to normal, was seen in the trans-
genic mice on a pT   background. Similar observations
have been made in mice expressing TCR transgenes. This
may reflect the inappropriate prolonged expression of the
pre-TCR that is a variable characteristic of transgenic mice.
It is known that constitutively activated lck provokes loss of
Figure 3. Schematic comparison of different
transgenic lines. Two parameters of thymocyte
phenotype (DP or  /  cell numbers) segregate to-
gether in different transgenic lines, but segregate
variably with thymus size. Gradation of shading
represents movement away from wild-type pheno-
type (see key).
Table III. Allelic Exclusion Occurs in the p300 P
Transgenic Line
Allelic exlusion
Allelic
inclusion
1VDJ  VDJ /VDJ  VDJ /DJ VDJ /VDJ 
3320
p300DP V 8.1J 2.3 V 8.2J 2.3
V 8.3J 1.1
V 2J 1.5
V 8.2J 2.1 V 12J 2.6
V 9J 2.6 V 9J 1.5
Allelic exclusion was assessed in single DP cells taken from thymi of
pT  /  mice expressing the p300 P transgene as described in Materials
and Methods. Of the eight single cells tested, none expressed more than
one correctly rearranged V  chain. The productive VDJ rearrangement
of the V  chain is shown.701 Gibbons et al. Brief Definitive Report
DP cells (29) possibly because the cells interpret continued
signaling as a negative selection stimulus. Sustained expres-
sion of the pre-TCR may do likewise. Ordinarily, the pre-
TCR is expressed at very low levels, and may be easily dis-
placed by TCR /  after TCR  gene rearrangement. In
transgenic mice, the physiologic expression of pT  will not
be precisely mimicked because of the heterologous pro-
moter elements, and because of integration sites that will
vary from founder to founder. Additionally, the displace-
ment of pT  from TCR  will likely depend on active sig-
naling mechanisms that regulate the stability and intracellu-
lar localization of the pT  protein (30). These mechanisms
may not function properly in the context of mutant pT 
transgenes. For these various reasons, the transgenic mice
may harbor a situation similar to that reported in lck trans-
genic mice. These are significant qualifications that must be
applied to the interpretation of such transgenic studies.
The simplest explanation for the biological activity of
very small forms of pT  is that pT  functions merely to
stabilize the   chain (aiding interaction with CD3 and
other downstream signaling molecules), and that a mini-
mal peptide of pT  is sufficient to accomplish this. This is
consistent with other instances of expression of truncated
pT  or TCR  alleles. For example, mice transgenic for a
TCR  chain lacking the V  region showed appropriate
DN to DP transition (31). The biological activity of truncated
versions of pT  is consistent with evidence that, indepen-
dent of any ligand, the pre-TCR spontaneously clusters
and associates with signaling molecules such as p56lck, CD3
molecules, and Zap-70 via sequestration in lipid rafts (20).
Presumably all active forms of pT  will elicit signaling to
nuclear factor (NF)- B implicated in promoting cell sur-
vival (26), and Vav-1 and Rac-1 (32, 33) implicated in
modulating actin dynamics that are important in spatially
orienting signaling molecules to coordinate and sustain sig-
nal transduction (for a review, see reference 34). Indeed,
electrophoretic mobility shift assays indicate high levels of
NF- B activity in DN thymocytes from pT  transgenic
mice (unpublished data). Nonetheless, it may be that signal-
ing from the physiologic pre-TCR; signaling from a pre-
TCR containing the pT -C  chimeric molecule, and sig-
naling in the absence of the pre-TCR but via cross-linking
CD3, each activate the same signaling molecules, but by
different means. For example, the palmitoylation of the
juxtamembranous Cys residue present in pT  that is impli-
cated in raft association, cannot obviously occur in the
pT  C  chimeric protein that lacks the juxtamembrane
cysteine. Yet, both of the pT  C  transgenic lines
showed comparable restoration of thymocyte phenotypes,
and were not obviously less effective than the other trans-
genes. Possibly, the pT  C  protein facilitates signal
transduction largely independent of raft association, because
the connecting peptide of C  (as opposed to the equivalent
domain in pT ) has a much stronger association with
CD3  (35). This would be consistent with the hypothesis
that regulated activation of common downstream signaling
pathways is the rate determining step to  -selection, and
can be achieved by distinct, albeit related mechanisms.
If only a very small part of pT  is required for its func-
tion, the question arises as to why pT  shows conservation
of its structure. One explanation is that the biological activ-
ity of the pre-TCR is so potent that many of its structural
features are essential for downregulation, ensuring that the
pre-TCR is expressed only at appropriate levels only dur-
ing the appropriate time window. In addition to the low
level and restricted time frame of pre-TCR expression,
several other experiments are suggestive of this. For exam-
ple, sustained expression of a transgenic TCR  allele that
lacks the V region led to thymic lymphomas (36). Al-
though such lymphomas did not characterize any of the
several pT  transgenic mice reported here, this may be be-
cause ectopically expressed pT  can be displaced, albeit in-
efficiently, by TCR , whereas a mutant TCR  chain
would not be, thus sustaining ligand-independent signaling.
Likewise, severe lymphomas with some characteristics of
pre-T cells (including sustained pT  expression) developed
with  80% penetrance in several lines of mice transgenic
for an activated form of Notch 3, the regulated expression
of which normally characterizes the  -selection stage (for a
review by Rothenberg, see reference 37). In striking illus-
tration of the potency of sustained pre-TCR signaling, the
development of Notch 3–induced tumors is dependent on
pT  expression (unpublished data).
According to this view, the pre-TCR is a potent agent
of cell growth and survival that must be downregulated af-
ter  -selection. Therefore, there are likely to be active sig-
naling components of the pre-TCR pathway, and possibly
an as yet unidentified ligand that may target regions of
pT  in order to negatively regulate its expression and ac-
tivity. This would lead to conservation of those regions of
pT . This remains to be tested biochemically, although
the recent report that the pT  tail can serve as an endo-
plasmic reticulum retention signal is consistent with this
outlook (38). Studies of pre-B cell receptor signaling have
indicated that the expression level of pre antigen receptors
is a product both of the structure of pre-antigen receptor
chains and the cell biological characteristics unique to the
immature cells in which the pre-antigen receptors are ex-
pressed (39).
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